Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

The company unveiled plans last week to test its GLP-1/glucagon dual receptor agonist in alcohol use disorder and ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

Further, it is also an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Lilly launches Mounjaro in India, offering new option to treat obesity and type 2 diabetes: Our Bureau, Bengaluru Thursday, ...

Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management ...